Tallac Therapeutics

Novel Cancer Immunotherapies

ALTA-002 Clin0 solid tumors; 3 undisclosed programs RD solid tumors

Tallac Therapeutics is harnessing the power of both the innate and adaptive immune system to develop cancer therapeutics. Antibody drug conjugates (ADCs) couple the specificity of antibodies with functional payloads that can be used to trigger events within the body. Tallac is building a pipeline of oligonucleotide-based ADC candidates including novel Toll-like Receptor Agonist Antibody Conjugates (TRAACs) to systematically deliver a potent Toll-like receptor agonist and trigger immune activation within the tumor microenvironment. Tallac currently has two TRAAC programs in clinical development.